{
  "id": 9586482,
  "title": "FDA upgrades Vitruvias Therapeutics recall: Superpotent thyroid tablets could trigger heart problems; who is at risk?",
  "url": "https://urgent.news/2026/09/24/fda-upgrades-vitruvias-therapeutics-recall-superpotent-thyroid",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-24T16:52:35.000Z",
  "source": {
    "name": "Live Mint",
    "slug": "live-mint",
    "url": "https://www.livemint.com/news/us-news/fda-upgrades-vitruvias-therapeutics-recall-superpotent-thyroid-tablets-could-trigger-heart-problems-who-is-at-risk-11790266807660.html"
  },
  "original_language": "en",
  "account": "The US Food and Drug Administration (FDA) has elevated the recall status of Vitruvias Therapeutics' thyroid tablets due to potential \"superpotent\" thyroid hormone levels that could lead to serious health complications. Classified as a Class I recall, this indicates the product could cause severe health consequences or even death. The recall pertains to a specific lot (504950, NDC 69680-166-00) of Thyroid Tablets USP 30 mg, with an expiration date of September 30, 2026. Though around 3,655 units were distributed, around 1,955 were actually sold.\n\nThe recall was prompted by concerns that the affected tablets may contain excessive thyroid hormone levels, potentially leading to overactive thyroid conditions. Symptoms may include weight loss, heat intolerance, fatigue, high blood pressure, chest pain, rapid heart rate, and irregular heart rhythms. The FDA emphasizes that the risk is heightened in vulnerable populations, especially elderly patients, pregnant women, and infants. These groups may face more severe consequences due to extended exposure to excessive thyroid hormones.\n\nFor those currently taking the recalled tablets, the FDA advises continuing the medication until consulting with a healthcare professional, who can provide guidance on next steps or arrange for a replacement prescription. Vitruvias Therapeutics encourages patients with questions to contact them at safety@vitruvias.com or (256) 239-9373. The company, which announced it had ceased operations, has transferred all remaining products to H2-Pharma LLC.",
  "summary": "The FDA has classified Vitruvias Therapeutics' recall of thyroid tablets as Class I due to potential superpotency, posing a risk of serious health issues. The affected lot includes approximately 3,655 units.",
  "key_points": [
    "FDA upgrades Vitruvias Therapeutics recall to Class I due to superpotent thyroid hormone risk",
    "1,955 units of Thyroid Tablets USP 30 mg (lot 504950) sold to vulnerable populations",
    "Elderly, pregnant women, and infants at heightened risk of severe health complications"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}